Description
About
Manjishtadi Kashaya Gulika Tablet is a classical Ayurvedic herbal tablet formulated from the Manjishtadi Kashaya. It is traditionally used for blood purification, liver health, and urinary disorders. The tablet form provides a convenient and easy-to-administer alternative to the decoction (kashayam) while retaining its detoxifying and rejuvenating properties.
Uses
-
Purifies blood and supports liver function
-
Helps manage urinary disorders, burning sensation, and kidney health
-
Supports menstrual health and reduces inflammation
-
Useful in skin disorders like rashes, eczema, and pigmentation
-
Promotes overall detoxification and vitality
Benefits
-
Acts as a natural blood purifier and detoxifier
-
Reduces inflammation and oxidative stress
-
Supports liver and kidney health
-
Improves skin texture and complexion
-
Convenient alternative to traditional Kashayam (decoction)
Different Names in Different Languages
-
Tamil: மஞ்சிஸ்தாடி கஷாய குழிகா மாத்திரை
-
Hindi: मंजिष्ठादी कषाय गोली
-
Telugu: మంజిష్టాది కషాయం గులికా టాబ్లెట్
-
Kannada: ಮಂಜಿಷ್ಟಾದಿ ಕಷಾಯ ಗುಲಿಕಾ ಟ್ಯಾಬ್ಲೆಟ್
-
Malayalam: മഞ്ജിഷ്ടാടി കഷായ ഗുലികാ ടാബ്ലറ്റ്
-
English: Manjishtadi Kashaya Gulika Tablet / Ayurvedic Blood Purifier Tablet
Key Ingredients (Common)
-
Manjishta (Rubia cordifolia) – blood purification and liver support
-
Triphala (Haritaki, Amalaki, Bibhitaki) – digestive and detoxifying
-
Other herbs as per classical Manjishtadi Kashaya formulation for urinary, liver, and skin health
Dosage & Administration
-
Adults: 1–2 tablets twice daily with warm water or as directed by an Ayurvedic physician
-
Children: Only under medical supervision
-
Can be taken after meals for better absorption
-
Continue for prescribed duration for effective results
Precautions
-
Take under medical supervision, especially in children, pregnant, and lactating women
-
Avoid exceeding the recommended dosage
-
Store in a cool, dry place, away from sunlight
-
People with chronic medical conditions should consult a physician before use
Reviews
There are no reviews yet.